The Role of Skin Microecology in Diabetic Skin Lesions
Explore the Role of Skin Microecology in Diabetic Skin Lesions Based on Multi-omics Data Analysis
Visão geral do estudo
Status
Condições
Descrição detalhada
The study intends to explore the mechanism of diabetic skin micro-ecology in diabetic skin diseases, and find new ways of early screening and prevention for diabetic foot.
This study is a prospective observational study. Adult participants were divided into the following 5 groups (n=200, 40 in each group): control group, very low-risk group, low-risk group, moderate-risk group, and high-risk group. Sterile rayon tipped swabs were pre-moistened with a sterile solution containing 0.15 M NaCl and 0.1% Tween 20. All swabs samples were collected from the intact skin at plantar anterior. And the skin cotton swab was subjected to 16s rDNA high-throughput sequencing, metagenomic sequencing methods, etc. Based on the result, the investigators will analyse the change of the cutaneous microbiome in DM as the disease condition progresses.
The skin tissues of the control group and observation group who met the inclusion criteria were also collected during surgical operations, and pathological and immunohistochemistry tests were performed respectively to analyze the pathological changes of diabetic skin tissues in different disease progressions.
According to the results of multi-omics analysis, the research team screen for the specific flora. Then sort out and culture specific strains, and establish mouse model of microbiota transplantation in order to explore the effects of regulating skin microecology on diabetic skin lesions through different treatment methods such as hypoglycemic drugs and probiotic emulsions.
Researchers will conduct telephone follow-ups of diabetic patients, collect data, and statistically analyze the impact of changes in the skin microecology of diabetic patients on the occurrence of diabetic foot ulcers.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Xiaoyan Tan
- Número de telefone: 02062786842
- E-mail: nfyykyc@163.com
Estude backup de contato
- Nome: Shili Zhang
- Número de telefone: +86-17817182600
- E-mail: sallyz11@163.com
Locais de estudo
-
-
Guangdong
-
Guangzhou, Guangdong, China, 518000
- Recrutamento
- Nanfang Hospital
-
Contato:
- Xiaoyan Tan
- Número de telefone: 02061641036
- E-mail: nfyykyc@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
1. Surface skin cotton swab collection
(1) Observation group: In the endocrinology department of Nanfang hospital, the patient were diagnosed with type 2 diabetes to the WHO 1999 diagnostic criteria for diabetes.
(2) Control group:
- Control subjects that was ruled out diabetes according to the WHO 1999 diagnostic criteria for euglycemia.
- Age ≥18 years, the patient and (or) his family members know and agree to participate in this study.
2. Skin tissue collection
(1) Observation group:
- The patient was diagnosed with type 2 diabetes in the Endocrinology Department, Burns Department, Traumatology Orthopedics, Plastic Surgery in Nanfang hospital.
- Patients who need surgical operations such as debridement and amputation below the knee joint due to various reasons such as diabetic foot osteomyelitis, fractures, car accidents and so on.
(2) Control group:
- The patient without type 2 diabetes in the Endocrinology Department, Burns Department, Traumatology Orthopedics, Plastic Surgery in Nanfang hospital.
- Patients who need surgical operations such as debridement and amputation below the knee joint due to various reasons such as post-traumatic foot osteomyelitis, fractures, car accidents and so on.
- Age ≥18 years, the patient and (or) his family members know and agree to participate in this study.
Exclusion Criteria:
The patients Including other skin diseases, using medically prescribed soap for bathing, using cosmetics on the feet, suffering from severe liver and kidney disease, immune system disease, HIV infection, malignant tumors, or using immunosuppressive drugs within the first four weeks. The patient or (and) their family members refused to participate in this study.
The researchers judged that they are not suitable to participate in this research.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
group ND
control group without DM non-intervention
|
|
group VD
very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD). non-intervention |
|
group LD
low-risk group: diabetic patient with LOPS or PAD non-intervention
|
|
group MD
moderate-risk group: diabetic patient with LOPS + PAD non-intervention
|
|
group HD
high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:
non-intervention |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
omics analysis of skin microbiome
Prazo: from September 2020 to July 2021
|
Compared with non-diabetic patients, the differences in skin microbiome of diabetic patients with different disease progression.
|
from September 2020 to July 2021
|
|
change of skin pathology in DM
Prazo: From August 2021 to July 2024
|
The pathological changes of the skin tissues of diabetic patients with different disease progression.
|
From August 2021 to July 2024
|
|
The incidence of developing into diabetic foot among the groups
Prazo: From August 2023 to July 2025
|
Follow-up for 2 years to assess the impact of changes in the skin microecology of diabetic patients on the occurrence of diabetic foot ulcers
|
From August 2023 to July 2025
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NFEC-2020-306
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .